替加环素治疗重症患者呼吸机相关性肺炎
发布时间：2019-03-27 12:22
【摘要】：目的评价替加环素治疗重症患者呼吸机相关性肺炎(VAP)的临床疗效与安全性。方法选取2011年1月1日至2013年5月31日山东大学齐鲁医院重症监护病房的VAP患者33例,给予替加环素治疗,初始剂量100 mg,维持剂量50 mg,静脉滴注,每隔12 h注射1次,根据患者具体病情确定给药疗程。评价患者的临床成功率、细菌清除率及安全性。结果入组病例37例,最终可评价病例33例,临床成功率61%(20/33)。共分离得到36株多重耐药菌,均对替加环素敏感,总清除率61%(22/36),其中分离率最高的鲍曼不动杆菌清除率60%(18/30)。不良反应以消化道症状为主,经临床对症治疗后好转。6例于治疗28 d内死亡。结论替加环素治疗危重患者VAP疗效确切,耐受性良好。
[Abstract]:Objective to evaluate the efficacy and safety of tegacycline in the treatment of severe ventilator-associated pneumonia (VAP). Methods from January 1, 2011 to May 31, 2013, 33 VAP patients in the intensive care unit of Qilu Hospital of Shandong University were treated with tegacycline. The initial dose was 100 mg, maintenance dose 50 mg, intravenous drip, once every 12 hours. The course of treatment was determined according to the patient's specific condition. To evaluate the clinical success rate, bacterial clearance rate and safety of the patients. Results 37 cases were enrolled and 33 cases were finally evaluated. The clinical success rate was 61% (20 / 33). A total of 36 strains of multidrug-resistant bacteria were isolated, all of which were sensitive to tegacycline. The total clearance rate was 61% (22 / 36), and that of Acinetobacter baumannii with the highest isolation rate was 60% (18 / 30). The adverse reactions were mainly alimentary tract symptoms and improved after clinical symptomatic treatment. 6 cases died within 28 days of treatment. Conclusion Tegacycline is effective and tolerable in the treatment of VAP in critically ill patients.
【作者单位】： 山东大学齐鲁医院重症医学科;山东大学齐鲁医院感染管理处;
【基金】：卫生部国家临床重点专科建设项目(2011-873) 中华医学会临床医学科研专项(1103016060)
【分类号】：R563.1
本文编号：2448174
[Abstract]:Objective to evaluate the efficacy and safety of tegacycline in the treatment of severe ventilator-associated pneumonia (VAP). Methods from January 1, 2011 to May 31, 2013, 33 VAP patients in the intensive care unit of Qilu Hospital of Shandong University were treated with tegacycline. The initial dose was 100 mg, maintenance dose 50 mg, intravenous drip, once every 12 hours. The course of treatment was determined according to the patient's specific condition. To evaluate the clinical success rate, bacterial clearance rate and safety of the patients. Results 37 cases were enrolled and 33 cases were finally evaluated. The clinical success rate was 61% (20 / 33). A total of 36 strains of multidrug-resistant bacteria were isolated, all of which were sensitive to tegacycline. The total clearance rate was 61% (22 / 36), and that of Acinetobacter baumannii with the highest isolation rate was 60% (18 / 30). The adverse reactions were mainly alimentary tract symptoms and improved after clinical symptomatic treatment. 6 cases died within 28 days of treatment. Conclusion Tegacycline is effective and tolerable in the treatment of VAP in critically ill patients.
【作者单位】： 山东大学齐鲁医院重症医学科;山东大学齐鲁医院感染管理处;
【基金】：卫生部国家临床重点专科建设项目(2011-873) 中华医学会临床医学科研专项(1103016060)
【分类号】：R563.1
【相似文献】
相关期刊论文 前3条
1 王艳红;吴本权;罗进梅;黄静;;替加环素联合头孢哌酮-舒巴坦治疗医院获得性泛耐药鲍氏不动杆菌肺炎10例[J];中国新药与临床杂志;2014年03期
2 张杰根;戴富林;韩硕;王刚;;替加环素联合舒巴坦治疗泛耐药鲍氏不动杆菌肺部感染的临床疗效观察[J];中华医院感染学杂志;2014年01期
3 ;[J];;年期
相关会议论文 前1条
1 阮肇扬;吕群;马潜;戴一帆;冯哲敏;;替加环素治疗碳青霉烯耐药肺炎克雷伯菌呼吸机相关性肺炎2例体会[A];华东地区第13届中青年呼吸论坛论文集[C];2012年
相关硕士学位论文 前1条
1 屈庆会;替加环素与舒巴坦联合应用对泛耐药鲍曼不动杆菌体外抗菌活性的研究[D];泰山医学院;2013年
，本文编号：2448174
本文链接：https://www.wllwen.com/yixuelunwen/huxijib/2448174.html
最近更新
教材专著
